AstraZeneca announces 'robust' results from anti-Covid drug trial
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
January 30, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, JANUARY 30, 2023
AstraZeneca announces 'robust' results from anti-Covid drug trial

Coronavirus chronicle

BSS/AFP
19 November, 2021, 11:25 am
Last modified: 19 November, 2021, 11:29 am

Related News

  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • US foresees annual Covid boosters, just like flu: Officials
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • From December no Covid-19 vaccine, except a booster dose, will be given
  • S Korea approves first domestically developed Covid vaccine

AstraZeneca announces 'robust' results from anti-Covid drug trial

A six-month follow-up trial "showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination", it said in a statement.

BSS/AFP
19 November, 2021, 11:25 am
Last modified: 19 November, 2021, 11:29 am
Photo/courtesy
Photo/courtesy

Pharmaceutical giant AstraZeneca on Thursday announced that clinical trials of an antibody-based Covid-19 drug had shown robust efficacy and long-term prevention.

The Anglo-Swedish laboratory follows in the footsteps of US firms Merck and Pfizer, which announced in October and early November respectively that they had developed drugs that could prevent severe forms of the disease, and that could be taken at the first sign of symptoms.

The AstraZeneca drug AZD7442, made from a combination of two antibodies, has been undergoing final stage clinical trials to assess its safety and efficacy.

A six-month follow-up trial "showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination", it said in a statement.

One 300mg IM dose reduced the risk of developing symptomatic COVID-19 compared to placebo by 83 percent, it added.

More than 75 percent of participants had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, but no severe cases were recorded.

Another trial to test its efficacy in treating those already suffering from "mild to moderate" Covid symptoms showed that one 600mg IM dose reduced the risk of developing severe illness or death by 88 percent.

"These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives," said Hugh Montgomery, professor of intensive care medicine at University College London.

"Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination."

AstraZeneca said the full results of both trials would be submitted for publication to a peer-reviewed medical journal.

It has already submitted an application to US regulators for approval of the drug to treat Covid-19.

AstraZeneca's separate Covid vaccine, developed with the University of Oxford, helped enable Britain's speedy Covid vaccination drive after it was approved in December 2020.

Top News / World+Biz / Health

AstraZeneca / Covid -19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Collected
    Economic slump drags down growth in VAT collection from big cos
  • It's corruption that bites business harder: CPD
    It's corruption that bites business harder: CPD
  • Import slowdown to affect economic growth: ADB country head
    Import slowdown to affect economic growth: ADB country head

MOST VIEWED

  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent
  • Sean Bagley, 14, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    Updated Covid vaccines prevented illness from latest variants -CDC

Related News

  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • US foresees annual Covid boosters, just like flu: Officials
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • From December no Covid-19 vaccine, except a booster dose, will be given
  • S Korea approves first domestically developed Covid vaccine

Features

Nandita Sharmin's journey to give organic skincare a new identity

Nandita Sharmin's journey to give organic skincare a new identity

16h | Mode
Illustration: TBS

'The silver lining is that the worst is sort of behind us': Hamid Rashid, UN economist

20h | Panorama
Photo: Bloomberg

BuzzFeed and AI are a match made in fad city

19h | Panorama
Snipe in flight. Photo: Enam Ul Haque

Baikka Beel: 'A world where snipe work late'

1d | Panorama

More Videos from TBS

Sarika Sabrin is waiting for a good film

Sarika Sabrin is waiting for a good film

10h | TBS Entertainment
Take your football game to the next level at Next Level academy

Take your football game to the next level at Next Level academy

11h | TBS SPORTS
“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

13h | TBS Round Table
What does Shahrukh has in his 770 million dollar property?

What does Shahrukh has in his 770 million dollar property?

1d | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

3
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

4
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

5
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]